Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours.

Nature communications

Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner S, Michalek RD, Karoly ED, Wallace DC, Languino LR, Speicher DW, Altieri DC.
PMID: 26085380
Nat Commun. 2015 Jun 18;6:7605. doi: 10.1038/ncomms8605.

No abstract available.

Cite
Chae YC, Angelin A, Lisanti S, et al. Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2015;6:7605doi: 10.1038/ncomms8605.
Chae, Y. C., Angelin, A., Lisanti, S., Kossenkov, A. V., Speicher, K. D., Wang, H., Powers, J. F., Tischler, A. S., Pacak, K., Fliedner, S., Michalek, R. D., Karoly, E. D., Wallace, D. C., Languino, L. R., Speicher, D. W., & Altieri, D. C. (2015). Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature communications, 67605. https://doi.org/10.1038/ncomms8605
Chae, Young Chan, et al. "Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours." Nature communications vol. 6 (2015): 7605. doi: https://doi.org/10.1038/ncomms8605
Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner S, Michalek RD, Karoly ED, Wallace DC, Languino LR, Speicher DW, Altieri DC. Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2015 Jun 18;6:7605. doi: 10.1038/ncomms8605. PMID: 26085380; PMCID: PMC4750482.
Copy Download .nbib Format: NLM
A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy.

Oncotarget

Bryant KG, Chae YC, Martinez RL, Gordon JC, Elokely KM, Kossenkov AV, Grant S, Childers WE, Abou-Gharbia M, Altieri DC.
PMID: 29348817
Oncotarget. 2017 Dec 11;8(68):112184-112198. doi: 10.18632/oncotarget.23097. eCollection 2017 Dec 22.

Reprogramming of mitochondrial functions sustains tumor growth and may provide therapeutic opportunities. Here, we targeted the protein folding environment in mitochondria by coupling a purine-based inhibitor of the molecular chaperone Heat Shock Protein-90 (Hsp90), PU-H71 to the mitochondrial-targeting moiety,...

Cite
Bryant KG, Chae YC, Martinez RL, et al. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget. 2017;8(68):112184-112198doi: 10.18632/oncotarget.23097.
Bryant, K. G., Chae, Y. C., Martinez, R. L., Gordon, J. C., Elokely, K. M., Kossenkov, A. V., Grant, S., Childers, W. E., Abou-Gharbia, M., & Altieri, D. C. (2017). A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget, 8(68), 112184-112198. https://doi.org/10.18632/oncotarget.23097
Bryant, Kelly G, et al. "A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy." Oncotarget vol. 8,68 (2017): 112184-112198. doi: https://doi.org/10.18632/oncotarget.23097
Bryant KG, Chae YC, Martinez RL, Gordon JC, Elokely KM, Kossenkov AV, Grant S, Childers WE, Abou-Gharbia M, Altieri DC. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget. 2017 Dec 11;8(68):112184-112198. doi: 10.18632/oncotarget.23097. eCollection 2017 Dec 22. PMID: 29348817; PMCID: PMC5762502.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries